Cyclophosphamate

DRUG3 trials

Sponsors

National Institute of Mental Health (NIMH), M.D. Anderson Cancer Center, Cellectar Biosciences, Inc.

Conditions

Alzheimer's DiseaseClear Cell CarcinomaGrowth FactorPhase 1Waldenstrom MacroglobulinaemiaWaldenstrom MacroglobulinemiaWaldenstrom Macroglobulinemia With Nodal DiseaseWaldenstrom's Macroglobulinaemia Refractory

Phase 1

Effects of an Anti-Inflammatory Drug in Alzheimer's Disease

CompletedNCT00013650

National Institute of Mental Health (NIMH)Alzheimer's Disease

Start: 2001-03-22End: 2008-04-21Target: 60Updated: 2017-07-02

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

RecruitingNCT07072234

M.D. Anderson Cancer CenterClear Cell Carcinoma, Growth Factor, Phase 1

Start: 2025-09-25End: 2030-02-01Target: 30Updated: 2026-04-29

Phase 3

Evaluation of Iopofosine I 131 vs. R-CD in WM Patients

Not yet recruitingNCT07766421

Cellectar Biosciences, Inc.Waldenstrom Macroglobulinaemia, Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia With Nodal Disease +2

Start: 2026-12-01End: 2035-01-01Target: 219Updated: 2026-08-14